The switch receptor T3/28 enhanced CD19 CAR-T cytotoxicity and cytokine production in vitro, and adoptive transfer of T3/28 CAR-T cells to tumor-bearing mice potentiated the therapeutic efficacy of CD19 CAR-T cells. This evidence concerns the gene CD19 and neoplasm.